Skip to main content
Journal cover image

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

Publication ,  Journal Article
Essock, SM; Schooler, NR; Stroup, TS; McEvoy, JP; Rojas, I; Jackson, C; Covell, NH; Schizophrenia Trials Network,
Published in: Am J Psychiatry
July 2011

OBJECTIVE: This randomized trial addressed the risks and benefits of staying on antipsychotic polypharmacy or switching to monotherapy. METHOD: Adult outpatients with schizophrenia taking two antipsychotics (127 participants across 19 sites) were randomly assigned to stay on polypharmacy or switch to monotherapy by discontinuing one antipsychotic. The trial lasted 6 months, with a 6-month naturalistic follow-up. Kaplan-Meier and Cox regression analyses examined time to discontinuation of assigned antipsychotic treatment, and random regression models examined additional outcomes over time. RESULTS: Patients assigned to switch to monotherapy had shorter times to all-cause treatment discontinuation than those assigned to stay on polypharmacy. By month 6, 86% (N=48) of those assigned to stay on polypharmacy were still taking both medications, whereas 69% (N=40) of those assigned to switch to monotherapy were still taking the same medication. Most monotherapy discontinuations entailed returning to the original polypharmacy. The two groups did not differ with respect to psychiatric symptoms or hospitalizations. On average, the monotherapy group lost weight, whereas the polypharmacy group gained weight. CONCLUSIONS: Discontinuing one of two antipsychotics was followed by treatment discontinuation more often and more quickly than when both antipsychotics were continued. However, two-thirds of participants successfully switched, the groups did not differ with respect to symptom control, and switching to monotherapy resulted in weight loss. These results support the reasonableness of prescribing guidelines encouraging trials of antipsychotic monotherapy for individuals receiving antipsychotic polypharmacy, with the caveat that patients should be free to return to polypharmacy if an adequate trial on antipsychotic monotherapy proves unsatisfactory.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Psychiatry

DOI

EISSN

1535-7228

Publication Date

July 2011

Volume

168

Issue

7

Start / End Page

702 / 708

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Schizophrenia
  • Psychotic Disorders
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Proportional Hazards Models
  • Polypharmacy
  • Male
  • Longitudinal Studies
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Essock, S. M., Schooler, N. R., Stroup, T. S., McEvoy, J. P., Rojas, I., Jackson, C., … Schizophrenia Trials Network, . (2011). Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry, 168(7), 702–708. https://doi.org/10.1176/appi.ajp.2011.10060908
Essock, Susan M., Nina R. Schooler, T Scott Stroup, Joseph P. McEvoy, Ingrid Rojas, Carlos Jackson, Nancy H. Covell, and Nancy H. Schizophrenia Trials Network. “Effectiveness of switching from antipsychotic polypharmacy to monotherapy.Am J Psychiatry 168, no. 7 (July 2011): 702–8. https://doi.org/10.1176/appi.ajp.2011.10060908.
Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011 Jul;168(7):702–8.
Essock, Susan M., et al. “Effectiveness of switching from antipsychotic polypharmacy to monotherapy.Am J Psychiatry, vol. 168, no. 7, July 2011, pp. 702–08. Pubmed, doi:10.1176/appi.ajp.2011.10060908.
Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH, Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011 Jul;168(7):702–708.
Journal cover image

Published In

Am J Psychiatry

DOI

EISSN

1535-7228

Publication Date

July 2011

Volume

168

Issue

7

Start / End Page

702 / 708

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Schizophrenia
  • Psychotic Disorders
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Proportional Hazards Models
  • Polypharmacy
  • Male
  • Longitudinal Studies
  • Humans